Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 15/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6940174 | 0.86 | MAOB (0.43) | DPP4DPP7RIPK1KDM4EAPAF1 | |
| SCHEMBL24915820 | 0.85 | KDM4E (0.41) | KDM4EAPAF1POLBMAPTRECQL | |
| SCHEMBL5813062 | 0.84 | DPP4 (0.46) | DPP4DPP9DPP7DPP8RIPK1 | |
| SCHEMBL8231920 | 0.80 | DPP4 (0.45) | DPP4DPP9DPP7DPP8RIPK1 | |
| SCHEMBL9292038 | 0.80 | USP2 (0.47) | KDM4EPOLBMAPTRECQLL3MBTL1 | |
| SCHEMBL9292034 | 0.80 | USP2 (0.47) | KDM4EPOLBMAPTRECQLL3MBTL1 | |
| SCHEMBL188142 | 0.79 | USP2 (0.54) | DPP4DPP9DPP7DPP8KDM4E | |
| SCHEMBL188143 | 0.79 | USP2 (0.54) | DPP4DPP9DPP7DPP8KDM4E | |
| SCHEMBL29430355 | 0.79 | USP2 (0.54) | DPP4DPP9DPP7DPP8KDM4E | |
| SCHEMBL31498017 | 0.79 | ITGB2 (0.44) | DPP4DPP9DPP7DPP8RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0921117-B2 | Acylguanidines | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-01-07 | — | — | EP | disclosed |
| US-20040044081-A1 | Diacyl-substituted guanidines, a process for their preparation, their use as medicament or diagnostic aid, and medicament containing them | HOECHST AKTIENGESELLSCHAFT | 2004-03-04 | — | — | US | disclosed |
| EP-0921117-B1 | Acylguanidines | AVENTIS PHARMA GMBH (DE) | 2003-12-10 | — | — | EP | disclosed |
| US-6632840-B1 | Inhibiting the Na+/H+ exchanger, treating at least one of arrhythmias and shock | HOECHST AKTIENGESELLSCHAFT (DE) | 2003-10-14 | — | — | US | disclosed |
| US-6436999-B1 | REACTING GUANIDINE AND CARBOCYCLIC ACIDS, TO FORM COMPOUNDS LIKE BIS(3-METHYLSULFONYL-4-I-PROPYLBENZOYL)GUANIDINE, USED FOR PROPHYLAXIS OF CARDIOVASCULAR DISORDERS AND AS PRODRUGS FOR SODIUM CHANNEL MODULATORS TO CONTROL BLOOD PRESSURE | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-08-20 | — | — | US | disclosed |
| EP-0921117-A2 | Acylguanidines | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-06-09 | — | — | EP | disclosed |
| EP-0640587-A1 | Diacyl substituted guanidins, process for their preparation, their use as medicament or diagnostic reagent and medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044081-A1 | Diacyl-substituted guanidines, a process for their preparation, their use as medicament or diagnostic aid, and medicament containing them | ADRA1B, ADRA1A, HYOU1 | DPP4 2413/4885DPP9 2830/4885DPP7 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.